Evidence map›Paper›PMID 31091694›Full record

ArticleMaterials (Basel, Switzerland)2019

The Fate of Osteoblast-Like MG-63 Cells on Pre-Infected Bactericidal Nanostructured Titanium Surfaces.

Jason V Wandiyanto, Vi Khanh Truong, Mohammad Al Kobaisi, Saulius Juodkazis, Helmut Thissen, Olha Bazaka, Kateryna Bazaka, Russell J Crawford, Elena P Ivanova

Open access · goldAbstract read
In one paragraph

Article in Materials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 42 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. TiOJournal of functional biomaterials · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jason V WandiyantoSchool of Science, Faculty of Science, Engineering and Technology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. jwandiyanto@swin.eud.au.
Vi Khanh TruongSchool of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC 3000, Australia. vi.khanh.truong@rmit.edu.au.
Mohammad Al KobaisiSchool of Science, Faculty of Science, Engineering and Technology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. makobaisi@swin.edu.au.
Saulius JuodkazisCenter for Micro-Photonics, Faculty of Science, Engineering and Technology, Swinburne University of Technology, Hawthorn, VIC 3122, Australia. Sjoudkazis@swin.edu.au.
Helmut ThissenCSIRO Manufacturing, Clayton, VIC 3168, Australia. helmut.thiessen@csiro.com.
Olha BazakaSchool of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC 3000, Australia. olga.bazaka@rmit.edu.au.
Kateryna BazakaInstitute for Future Environments, Queensland University of Technology, GPO Box 2434, Brisbane, QLD 4001, Australia. katerina.bazaka@qut.edu.au.
Russell J CrawfordSchool of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC 3000, Australia. russell.crawford@rmit.edu.au.
Elena P IvanovaSchool of Science, College of Science, Engineering and Health, RMIT University, Melbourne, VIC 3000, Australia. elena.ivanova@rmit.edu.au.ORCID 0000-0002-5509-8071
RMIT University · AUSwinburne University of Technology · AUCSIRO Manufacturing · AUQueensland University of Technology · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomaterials that have been newly implanted inside the body are the substratum targets for a "race for the surface", in which bacterial cells compete against eukaryotic cells for the opportunity to colonize the surface. A victory by the former often results in biomaterial-associated infections, which can be a serious threat to patient health and can undermine the function and performance of the implant. Moreover, bacteria can often have a 'head start' if implant contamination has taken place either prior to or during the surgery. Current prevention and treatment strategies often rely on systemic antibiotic therapies, which are becoming increasingly ineffective due to a growing prevalence of antibiotic-resistant bacteria. Nanostructured surfaces that kill bacteria by physically rupturing bacterial cells upon contact have recently emerged as a promising solution for the mitigation of bacterial colonization of implants. Furthermore, these nanoscale features have been shown to enhance the adhesion and proliferation of eukaryotic cells, which is a key to, for example, the successful osseointegration of load-bearing titanium implants. The bactericidal activity and biocompatibility of such nanostructured surfaces are often, however, examined separately, and it is not clear to what extent bacterial cell-surface interactions would affect the subsequent outcomes of host-cell attachment and osseointegration processes. In this study, we investigated the ability of bactericidal nanostructured titanium surfaces to support the attachment and growth of osteoblast-like MG-63 human osteosarcoma cells, despite them having been pre-infected with pathogenic bacteria. MG-63 is a commonly used osteoblastic model to study bone cell viability, adhesion, and proliferation on the surfaces of load-bearing biomaterials, such as titanium. The nanostructured titanium surfaces used here were observed to kill the pathogenic bacteria, whilst simultaneously enhancing the growth of MG-63 cells in vitro when compared to that occurring on sterile, flat titanium surfaces. These results provide further evidence in support of nanostructured bactericidal surfaces being used as a strategy to help eukaryotic cells win the "race for the surface" against bacterial cells on implant materials.

Indexed as

competitive colonizationmechano-bactericidal surfacesMG-63titanium

Identifiers

PMID31091694
PMCPMC6567816
OpenAlexW2945494155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.